Evotec (EVT) – aksjekurser og nyheter

EVT:FRA

Evotec

5,09 €

−1,17%

(−0,060) 1 D

3. juli, 22:00:00 GMT+2 · EUR

Alle symboler

1 D

5 D

1 M

6 M

I år

1 Å

5 Å

MAKS

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for EVT …

Åpne

5,18 €

Høy

5,18 €

Lav

5,09 €

Markedsverdi

904,68 mill.

Snittvolum

2,74k

Volum

1,76k

52 u høy

7,80 €

52 u lav

4,02 €

EPS

−1,09 €

Utestående aksjer

148,72 mill.

Antall ansatte

Åpne

5,18 €

Høy

5,18 €

Lav

5,09 €

Markedsverdi

904,68 mill.

Snittvolum

2,74k

Volum

1,76k

52 u høy

7,80 €

52 u lav

4,02 €

EPS

−1,09 €

Utestående aksjer

148,72 mill.

Antall ansatte

Relaterte aksjer

Hannover Re Common Stock

Nyhetssaker

Fra kilder på nettet

Simply Wall Street

for 2 døgn siden

Evotec (XTRA:EVT) Launches J.TRAIN, Is The Stock Trading At A Discount?

https://www.dars.gov.et/

for 1 måned siden

Evotec Q1 2026 Earnings: EPS Falls Sharply Short of Estimates Amid Operational Pressures - Earnings Risk Report

Profil

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development. The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more. On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia

Om Evotec

Administrerende direktør-

Ansatte4,53k

Grunnlagt1993

Hovedkontor-

Sektor-

Nettstedevotec.com

Alle verdier i EUR	juni 2025	sep. 2025	des. 2025	mars 2026
Inntekt	171,24 mill.	163,89 mill.	253,27 mill.	156,64 mill.
Varekostnad	162,64 mill.	163,95 mill.	174,81 mill.	158,21 mill.
Direkte driftskostnader	162,64 mill.	163,95 mill.	174,81 mill.	158,21 mill.
Utgifter til forskning og utvikling	8,21 mill.	8,71 mill.	9,83 mill.	10,08 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	41,61 mill.	42,31 mill.	44,35 mill.	43,79 mill.
Driftskostnader	37,19 mill.	43,53 mill.	55,25 mill.	44,85 mill.
Totale driftskostnader	199,83 mill.	207,48 mill.	230,06 mill.	203,07 mill.
Driftsinntekter	−28,60 mill.	−43,59 mill.	23,21 mill.	−46,42 mill.
Andre ikke-operasjonelle inntekter	−10,64 mill.	1,19 mill.	−33,96 mill.	1,89 mill.
EBT inkludert uvanlige elementer	−43,42 mill.	−42,96 mill.	29,46 mill.	−122,18 mill.
EBT uten uvanlige elementer	−44,67 mill.	−43,36 mill.	18,35 mill.	−47,40 mill.
Kostnad for inntektsskatt	59,00k	127,00k	14,84 mill.	−244,00k
Faktisk avgiftssats	−0,14 %	−0,30 %	50,37 %	0,20 %
Andre driftskostnader	−12,63 mill.	−7,50 mill.	1,07 mill.	−9,02 mill.
Nettoinntekt	−43,48 mill.	−43,09 mill.	14,62 mill.	−121,94 mill.
Netto fortjenestemargin	−25,39 %	−26,29 %	5,77 %	−77,84 %
Resultat per aksje	-	−0,24	-	-
Rente- og investeringsinntekter	1,21 mill.	841,00k	11,84 mill.	-
Rentekostnader	−6,00 mill.	−2,28 mill.	-	−2,58 mill.
Netto rentekostnader	−4,79 mill.	−1,44 mill.	11,84 mill.	−2,58 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	−3,42 mill.	−18,27 mill.	41,91 mill.	−22,60 mill.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

AI-innhold kan inneholde feil. Finn ut mer

HjelpSend tilbakemeldingPersonvern Vilkår Ansvarsfraskrivelse

Finance

Utforskning